Can eye drops safely replace reading glasses in older adults?

Exclusion Criteria17

• Medical conditions
• Uncontrolled systemic disease or clinically significant disease state in any body system that, in the opinion of the investigator, could have affected the safety of the individual or interpretation of endpoint measures
• History of ocular pathology or intraocular surgery that, in the opinion of the investigator, could have affected the safety of the individual or interpretation of endpoint measures
• Contraindications for Vuity eye drops
• Known allergy or sensitivity to pilocarpine, other components in Vuity eye drops, or other cholinergic agonist medications
• Narrow iridocorneal angles that are at risk of angle-closure and physiological anisocoria of >1 mm between pupils, as these conditions could affect the safety of the individual or interpretation of endpoint measures
• Prior/Concomitant therapy
• Use of any topical prescription or over-the-counter ophthalmic medications that, in the opinion of the investigator, could have a substantial effect on visual function and affect interpretation of endpoint measures
• Use of systemic medications with potential ocular side effects, including topiramate, hydroxychloroquine, ethambutol, phosphodiesterase 5 inhibitors (sildenafil, vardenafil, tadalafil), or tamoxifen, that could have a substantial effect on visual function and affect interpretation of endpoint measures
• Use of systemic or intranasal anticholinergics and alpha-adrenergic receptor agonists with potential pupillary or accommodative effects, including oxymetazoline, tetrahydrozoline, phenylephrine, naphazoline, atropine, pilocarpine, beta-blockers, or antihistamines, that could have a substantial effect on visual function and affect interpretation of endpoint measures
• Use of systemic maprotiline, tricyclic antidepressants, or monoamine oxidase inhibitors, that could have a substantial effect on visual function and affect interpretation of endpoint measures
• Diagnostic assessments
• Astigmatic refractive error based on non-cycloplegic subjective refraction, defined as a magnitude of astigmatism of 1.00 Dioptres or higher.
• Monocular unaided distance visual acuities poorer than 0.20 logMAR (Snellen 6/9.5) in both eyes, as this may be indicative of significant ametropia that may affect the interpretation of endpoint measures
• Monocular best-corrected distance visual acuities poorer than 0.00 logMAR (Snellen 6/6) in both eyes, as this may be indicative of an underlying ocular condition or abnormality that may affect the safety of the individual or interpretation of endpoint measures
• Other
• Females who are not pregnant or breastfeeding, and are not considering becoming pregnant or donating eggs during the study or for ~30 days after the last dose of study intervention, as safety of Vuity eye drops has not been established for use in pregnancy and lactation.